Pneumosin

Drug category: Antimicrobial

Dosage form: Sterile injectable solution

Presentation: Each ml contains 300 mg of tilmicosin activity

Mechanism of Action:
Tilmicosin is produced semi- synthetically and is a member of the macrolide class of antibiotics. Tilmicosin inhibiting protein synthesis at the 50S ribosomal subunit. One study reports that 90% of the pasteurella hemolytica and pasteurella multocida isolates tested were sensitive to tilmicosin at concentration of 6.25mg/ ml

PHARMCOKINETICS:
Tilmicosin is effective as single subcutaneous injection lung concentrations of tillmicosin following injection are significantly higher than serum levels. In calves, lung concentrations of tilmicosin remained above the tilmicosin MIC 90% of  3.12 µg/ mg for pasteurella hemolytia for approximately 4 days following the single subcutaneous injection of tilmicosin at the recommended dose.

Uses:
Tilmicosine is indicated for the treatment of pneumonia in sheep and cattle associated with pasteurella hemolytica and p. multocide and other organisms sensitive to this drug and for treatment of ovine mastitis associated with staphylococcus aurerus and mycoplasma agalactiae.

Dosage and administration:
Inject only subcutaneously in sheep and cattle. Administer a single subcutaneous injection of 10 mg per kg bodyweight.(1ml per 30 kg bodyweight) In cattle, do not injection more than 25 ml per injection site. In cattle, injection under the skin behind the shoulders and over the ribs is suggested. In sheep, injection in fold of skin over the rib cage behind the shoulder is suggested.

Contra- indication, warning, etc.
Do not inject lambs weighting less than 15 kg.
Do not administer to goats and horse. Injection of the product in goats has been fatal. Do not use in cows producing milk for human consumption.
Do not administer intravenously. Intravenous injection in cattle and sheep has been fatal.

ADVERSE AND COMMON SIDE EFFECTS:
The toxic effects of tilmicosin appear to affect the cardiovascular system. As tilmicosin persists in tissues for several days, the cardiovascular system should be closely monitored and supportive treatment provided.
May cause sensitization by skin contact.

Contra- indication, warning, etc:
Exercise caution to avoid accidental self injection. In case of human injection, seak immediate medical attention. Occasionally a soft diffuse oedematous swelling may occur at the injection site. The swelling disappears with in five to eight days.
Avoid contact with eyes.
Keep out of the reach of children.  

Withdrawal period: cattle and sheep must not be slaughtered for human consumption for at least 28 days after treatment.
Ewe's milk must not be used for human consumption for atleast 12 days after treatment.

Pharmaceutical precautions:Store at room temperature, not exceeding 30^OC. Protect from direct sunlight. Do not freeze.

Package quantities: vial 20ml.